CANBRIDGE-B (01228) Raises HK$200.00 Million via Placement of 84.03 Million New Shares; Share Capital Expands 16.43%

Bulletin Express03-11

CANbridge Pharmaceuticals Inc. (HKEX: 01228, “CANBRIDGE-B”) announced that it has completed a share subscription under its general mandate on 10 March 2026. All conditions under the Subscription Agreement, first disclosed on 16 February 2026, have been fulfilled.

Key transaction terms • Shares issued: 84.03 million new ordinary shares • Subscription price: HK$2.38 per share • Gross proceeds: approximately HK$200.00 million • Effective date (“Closing”): 10 March 2026

Post-issuance capital structure • Issued share capital rose to 595.44 million shares from 511.41 million, representing a 16.43% increase. • The Subscriber’s holding jumped from 12.83 million shares (2.51%) to 96.86 million shares (16.26%), making it one of the largest shareholders. • Baheal’s stake was diluted to 16.32% from 19.00%. • Dr. James Xue’s aggregate interest (direct holdings, CTX Pharma Holdings Limited, and family trust) decreased to 7.03% from 8.18% due to dilution. • Public float (other public shareholders) declined to 60.27% from 70.17%.

Governance update The Board composition remains unchanged, with Dr. James Qun Xue continuing as Chairman and executive Director. The Board also includes two non-executive Directors and four independent non-executive Directors.

The completion of this subscription strengthens CANBRIDGE-B’s capital base, enlarges its shareholder register, and alters ownership percentages across existing shareholders without affecting board structure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117673563?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 06:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117673563","market":"us","top_or_hot":-1,"title":"CANBRIDGE-B (01228) Raises HK$200.00 Million via Placement of 84.03 Million New Shares; Share Capital Expands 16.43%","media":"Bulletin Express","content":"<p>CANbridge Pharmaceuticals Inc. (HKEX: 01228, “CANBRIDGE-B”) announced that it has completed a share subscription under its general mandate on 10 March 2026. All conditions under the Subscription Agreement, first disclosed on 16 February 2026, have been fulfilled.</p>\n<p>Key transaction terms  \n• Shares issued: 84.03 million new ordinary shares  \n• Subscription price: HK$2.38 per share  \n• Gross proceeds: approximately HK$200.00 million  \n• Effective date (“Closing”): 10 March 2026</p>\n<p>Post-issuance capital structure  \n• Issued share capital rose to 595.44 million shares from 511.41 million, representing a 16.43% increase.  \n• The Subscriber’s holding jumped from 12.83 million shares (2.51%) to 96.86 million shares (16.26%), making it one of the largest shareholders.  \n• Baheal’s stake was diluted to 16.32% from 19.00%.  \n• Dr. James Xue’s aggregate interest (direct holdings, CTX Pharma Holdings Limited, and family trust) decreased to 7.03% from 8.18% due to dilution.  \n• Public float (other public shareholders) declined to 60.27% from 70.17%.</p>\n<p>Governance update  \nThe Board composition remains unchanged, with Dr. James Qun Xue continuing as Chairman and executive Director. The Board also includes two non-executive Directors and four independent non-executive Directors.</p>\n<p>The completion of this subscription strengthens CANBRIDGE-B’s capital base, enlarges its shareholder register, and alters ownership percentages across existing shareholders without affecting board structure.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANBRIDGE-B (01228) Raises HK$200.00 Million via Placement of 84.03 Million New Shares; Share Capital Expands 16.43%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANBRIDGE-B (01228) Raises HK$200.00 Million via Placement of 84.03 Million New Shares; Share Capital Expands 16.43%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-11 06:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANbridge Pharmaceuticals Inc. (HKEX: 01228, “CANBRIDGE-B”) announced that it has completed a share subscription under its general mandate on 10 March 2026. All conditions under the Subscription Agreement, first disclosed on 16 February 2026, have been fulfilled.</p>\n<p>Key transaction terms  \n• Shares issued: 84.03 million new ordinary shares  \n• Subscription price: HK$2.38 per share  \n• Gross proceeds: approximately HK$200.00 million  \n• Effective date (“Closing”): 10 March 2026</p>\n<p>Post-issuance capital structure  \n• Issued share capital rose to 595.44 million shares from 511.41 million, representing a 16.43% increase.  \n• The Subscriber’s holding jumped from 12.83 million shares (2.51%) to 96.86 million shares (16.26%), making it one of the largest shareholders.  \n• Baheal’s stake was diluted to 16.32% from 19.00%.  \n• Dr. James Xue’s aggregate interest (direct holdings, CTX Pharma Holdings Limited, and family trust) decreased to 7.03% from 8.18% due to dilution.  \n• Public float (other public shareholders) declined to 60.27% from 70.17%.</p>\n<p>Governance update  \nThe Board composition remains unchanged, with Dr. James Qun Xue continuing as Chairman and executive Director. The Board also includes two non-executive Directors and four independent non-executive Directors.</p>\n<p>The completion of this subscription strengthens CANBRIDGE-B’s capital base, enlarges its shareholder register, and alters ownership percentages across existing shareholders without affecting board structure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01228","symbol_name":"北海康成-B","start_time":0,"source_url":"","article_id":"1117673563","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117673563","pubTimestamp":1773181397,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CANbridge Pharmaceuticals Inc. (HKEX: 01228, “CANBRIDGE-B”) announced that it has completed a share subscription under its general mandate on 10 March 2026. All conditions under the Subscription...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01228":"北海康成-B"},"translate_title":"CANBRIDGE-B(01228)配售8403万股新股集资2亿港元；股本扩大16.43%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01228":1},"content_text":"CANbridge Pharmaceuticals Inc. (HKEX: 01228, “CANBRIDGE-B”) announced that it has completed a share subscription under its general mandate on 10 March 2026. All conditions under the Subscription Agreement, first disclosed on 16 February 2026, have been fulfilled.\nKey transaction terms  \n• Shares issued: 84.03 million new ordinary shares  \n• Subscription price: HK$2.38 per share  \n• Gross proceeds: approximately HK$200.00 million  \n• Effective date (“Closing”): 10 March 2026\nPost-issuance capital structure  \n• Issued share capital rose to 595.44 million shares from 511.41 million, representing a 16.43% increase.  \n• The Subscriber’s holding jumped from 12.83 million shares (2.51%) to 96.86 million shares (16.26%), making it one of the largest shareholders.  \n• Baheal’s stake was diluted to 16.32% from 19.00%.  \n• Dr. James Xue’s aggregate interest (direct holdings, CTX Pharma Holdings Limited, and family trust) decreased to 7.03% from 8.18% due to dilution.  \n• Public float (other public shareholders) declined to 60.27% from 70.17%.\nGovernance update  \nThe Board composition remains unchanged, with Dr. James Qun Xue continuing as Chairman and executive Director. The Board also includes two non-executive Directors and four independent non-executive Directors.\nThe completion of this subscription strengthens CANBRIDGE-B’s capital base, enlarges its shareholder register, and alters ownership percentages across existing shareholders without affecting board structure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117673563","isCrawlerRequest":true}